This study is testing if buspirone, an FDA-approved medication, can help people with opioid use disorder (OUD) manage opioid withdrawal symptoms and cravings. You would receive either buspirone, lofexidine (another medication for withdrawal), or a placebo (an inactive substance) for about 10 days while undergoing a supervised opioid taper (gradual reduction of opioids). Researchers want to see if buspirone can reduce withdrawal symptoms, as measured by a survey called the Subjective Opiate Withdrawal Scale (SOWS), from two days before the taper until two days after. You could join if you are 18-75 years old, have moderate-to-severe OUD, and are interested in detoxification. The study aims to enroll 100 participants, but its current status is unclear.

Study design

This is a Phase II, three-group, double-blind, placebo-controlled randomized clinical trial. About 100 participants will be enrolled.

What's involved

You would stay in a clinical research unit for 10-12 days. During this time, you would receive study medication and undergo an opioid taper.

Compensation

Not stated in the trial record.

Follow-up

Your opioid withdrawal symptoms will be measured from two days before the opioid taper until two days after the taper.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.